October 2026's Top Insider-Owned Growth Stocks
Over the last 7 days, the United States market has remained flat, yet it is up 12% over the past year with earnings forecast to grow by 17% annually. In this environment, growth companies with high insider ownership can be particularly appealing as they often indicate strong confidence from those closest to the business in its future potential.
Top 10 Growth Companies With High Insider Ownership In The United States
| Name | Insider Ownership | Earnings Growth |
| Upstart Holdings (UPST) | 14.0% | 70.2% |
| Standard Nuclear (STDN) | 20.4% | 64.2% |
| Sable Offshore (SOC) | 11.3% | 71.3% |
| Precigen (PGEN) | 11.7% | 54% |
| Nu Holdings (NU) | 23.1% | 22.3% |
| Karman Holdings (KRMN) | 13.6% | 56.4% |
| Himax Technologies (HIMX) | 29.1% | 70.2% |
| Figure Technology Solutions (FIGR) | 21.4% | 33.1% |
| Energy Vault Holdings (NRGV) | 10.5% | 67.3% |
| Almonty Industries (ALM) | 10.8% | 58.3% |
Let's take a closer look at a couple of our picks from the screened companies.
Corcept Therapeutics (CORT)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Corcept Therapeutics Incorporated is a biopharmaceutical company focused on discovering and developing medications for severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States, with a market cap of $12.60 billion.
Operations: The company's revenue primarily comes from the discovery, development, and commercialization of pharmaceutical products, amounting to $830.81 million.
Insider Ownership: 10.7%
Corcept Therapeutics, with high insider ownership, is positioned for growth as its earnings are forecasted to grow significantly at 43.4% annually and revenue at 25.6%, outpacing the US market. Recent endorsements from diabetes associations highlight the potential of its drug mifepristone for managing hyperglycemia in type 2 diabetes patients. However, profit margins have declined from last year, and there has been significant insider selling recently.
- Get an in-depth perspective on Corcept Therapeutics' performance by reading our analyst estimates report here.
- Our comprehensive valuation report raises the possibility that Corcept Therapeutics is priced lower than what may be justified by its financials.
Nuvation Bio (NUVB)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Nuvation Bio Inc. is a clinical-stage biopharmaceutical company dedicated to developing cancer treatment product candidates, with a market cap of $1.57 billion.
Operations: The company generates revenue from oncology development activities, amounting to $169.90 million.
Insider Ownership: 18.9%
Nuvation Bio, characterized by high insider ownership, is poised for substantial growth with its revenue projected to grow 31.4% annually, outpacing the US market. The recent FDA approval of IBTROZI enhances its position in treating ROS1+ NSCLC. Despite a net loss of US$62.84 million in Q2 2026, the company forecasts profitability within three years and trades significantly below estimated fair value. Safety concerns include hepatotoxicity and QTc prolongation associated with IBTROZI use.
- Unlock comprehensive insights into our analysis of Nuvation Bio stock in this growth report.
- The analysis detailed in our Nuvation Bio valuation report hints at an deflated share price compared to its estimated value.
Standard Nuclear (STDN)
Simply Wall St Growth Rating: ★★★★★★
Overview: Standard Nuclear, Inc. operates as an independent advanced nuclear fuel company in the United States with a market cap of $1.92 billion.
Operations: The company generates revenue primarily from its TRISO Production segment, which amounts to $7.54 million.
Insider Ownership: 20.4%
Standard Nuclear, with significant insider ownership, is positioned for robust growth as its revenue is forecast to increase by 62% annually, surpassing the US market. Recent agreements with Antares and Radiant Industries secure long-term TRISO fuel supply, enhancing its domestic nuclear capabilities. Despite a net loss of US$3.42 million in Q2 2026, the company plans to achieve profitability within three years while trading well below estimated fair value. Facility expansions in Tennessee and Idaho further bolster production capacity.
- Click here and access our complete growth analysis report to understand the dynamics of Standard Nuclear.
- Upon reviewing our latest valuation report, Standard Nuclear's share price might be too pessimistic.
Key Takeaways
- Unlock our comprehensive list of 185 Fast Growing US Companies With High Insider Ownership by clicking here.
- Interested In Other Possibilities? The end of cancer? These 38 emerging AI stocks are developing tech that will allow early idenification of life changing disesaes like cancer and Alzheimer's.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com